Novartis

Novartis

Overview

Novartis AG is a global pharmaceutical company headquartered in Basel, Switzerland, with operations spanning over 140 countries. One of the world's largest healthcare companies, Novartis has a significant presence in neuroscience, with active programs in Alzheimer's disease, Parkinson's disease, and other neurological disorders["@novartis"].

Novartis has a long history in neuroscience research, having developed landmark treatments for multiple sclerosis, epilepsy, and other CNS conditions. The company's current neurodegeneration pipeline focuses on disease-modifying approaches targeting protein aggregation, neuroinflammation, and synaptic function["@novartis2024"].

Pipeline Overview

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| MFNZ-2313 | Undisclosed CNS target | Alzheimer's Disease | Phase 1 | Active |
| product candidate | [Tau](/proteins/tau) targeting | Alzheimer's Disease | Preclinical | Research |
| UNR161 | [LRRK2](/entities/lrrk2) inhibitor | Parkinson's Disease | Preclinical | Research |
| CJN-5 | α-synuclein targeting | Parkinson's Disease | Discovery | Research |
| Product candidate | Gene therapy | CNS disorders | Preclinical | Research |

Funding

Novartis

Overview

Novartis AG is a global pharmaceutical company headquartered in Basel, Switzerland, with operations spanning over 140 countries. One of the world's largest healthcare companies, Novartis has a significant presence in neuroscience, with active programs in Alzheimer's disease, Parkinson's disease, and other neurological disorders["@novartis"].

Novartis has a long history in neuroscience research, having developed landmark treatments for multiple sclerosis, epilepsy, and other CNS conditions. The company's current neurodegeneration pipeline focuses on disease-modifying approaches targeting protein aggregation, neuroinflammation, and synaptic function["@novartis2024"].

Pipeline Overview

| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| MFNZ-2313 | Undisclosed CNS target | Alzheimer's Disease | Phase 1 | Active |
| product candidate | [Tau](/proteins/tau) targeting | Alzheimer's Disease | Preclinical | Research |
| UNR161 | [LRRK2](/entities/lrrk2) inhibitor | Parkinson's Disease | Preclinical | Research |
| CJN-5 | α-synuclein targeting | Parkinson's Disease | Discovery | Research |
| Product candidate | Gene therapy | CNS disorders | Preclinical | Research |

Funding

• IPO: 1996 (NYSE: NVS)
• Market Cap: ~$210B (2026)
• 2025 Revenue: $51B
• 2024 Revenue: $48B
• R&D Investment: ~$9B annually
• Dividend: CHF 3.20 per share (2025)

[Alzheimer's Disease](/diseases/alzheimers-disease) Programs

MFNZ-2313

MFNZ-2313 is a first-in-class therapeutic candidate in Phase 1 clinical development for Alzheimer's disease. The program targets a novel mechanism distinct from amyloid and tau approaches, focusing on addressing neuroinflammation and synaptic dysfunction[@mfnz].

Mechanism:

• Novel CNS target
• Modulates neuroinflammatory pathways
• Protects synaptic function
• Disease-modifying potential

• Phase 1: First-in-human studies ongoing
• Primary objectives: Safety, tolerability, PK
• Secondary objectives: Target engagement biomarkers

Tau Targeting Programs

Novartis maintains multiple preclinical programs targeting tau pathology:

• Anti-tau antibodies: Monoclonal antibodies targeting various tau species
• Tau aggregation inhibitors: Small molecules preventing tau aggregation
• Tau PET tracers: Diagnostic imaging agents

[Parkinson's Disease](/diseases/parkinsons-disease) Programs

LRRK2 Inhibitor Program

Novartis is developing LRRK2 inhibitors for Parkinson's disease, targeting both genetic and sporadic forms:

• UNR161: Lead LRRK2 inhibitor program
• Mechanism: ATP-competitive inhibition of LRRK2 kinase
• Rationale: LRRK2 mutations are common in familial PD
• Status: Preclinical development

Alpha-Synuclein Programs

The company has discovery-stage programs targeting [alpha-synuclein](/proteins/alpha-synuclein):

• CJN-5: Novel alpha-synuclein targeting modality
• Antibody programs: Passive immunotherapy approaches
• Gene therapy: AAV-based delivery of therapeutic genes

Neuroscience Research Platforms

Novartis leverages multiple technology platforms for neuroscience drug discovery:

Key Capabilities

| Platform | Application |
|----------|-------------|
| Genomics | Target identification |
| Structural biology | Drug design |
| Antibody engineering | Biologics development |
| Gene therapy | AAV delivery |
| Stem cells | Disease modeling |

Research Focus Areas

• Protein homeostasis and aggregation
• [Neuroinflammation](/mechanisms/neuroinflammation) and [microglia](/cell-types/microglia-neuroinflammation)
• Synaptic function and plasticity
• [Mitochondrial](/mechanisms/mitochondrial-dysfunction) dysfunction
• [Neurodegeneration](/diseases/neurodegeneration) pathways

Clinical Development Infrastructure

Novartis maintains extensive CNS clinical trial capabilities:

• Global clinical trial network
• Specialized CNS trial sites
• Biomarker laboratories
• Digital health platforms
• Patient registries

Historical Neuroscience Programs

Novartis has a rich history in neuroscience:

Approved Treatments

• Gilenya (fingolimod): Multiple sclerosis
• Lucentis (ranibizumab): Wet AMD
• Zometa: Bone metastases

Discontinued Programs

• CPAA: Amyloid antibody (did not meet endpoints)
• BAY-239: Undisclosed CNS target

Partnerships

| Partner | Focus Area | Programs |
|---------|------------|----------|
| Amgen | Neuroscience | Collaboration |
| University of Basel | Research | Academic partnership |
| Multiple biotech | Co-development | Various |

Financial Information

• Annual revenue: ~$50 billion (2024)
• R&D budget: ~$9 billion annually
• Neuroscience allocation: Growing portfolio
• Market cap: ~$200 billion (2024)
• Employees: ~100,000 globally

Key Personnel

• Dr. Vasant Narasimhan - CEO
• Dr. Ronny Gal - Chief Marketing and Strategy Officer
• Dr. Shreeram Aradhye - President, Global Drug Development
• Dr. Fiona H. M. McMorrow - Global Head of Neuroscience

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [LRRK2](/genes/lrrk2)
• [Alpha-Synuclein](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Tau Pathology](/mechanisms/tau-pathology)
• [Roche](/companies/roche)
• [Biogen](/companies/biogen)
• [Eli Lilly](/companies/eli-lilly)

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Financial Information

Novartis is one of the world's largest pharmaceutical companies with substantial neuroscience R&D investment:

• [Market Cap**: ~$220 billion (2025)](/genes/ar)
• Annual R&D Budget: ~$10 billion total
• [Neuroscience Investment**: Estimated $1-2 billion annually](/investment)
• [Key Products**: Cosentyx, Entresto, Kymriah, Zolgensma](/genes/rest)

• [2024 revenue: Approximately $56 billion](/proteins/app)
• [Strong cash flow supporting R&D and acquisitions](/institutions/cas)
• [Strategic focus on innovative medicines and gene therapy](/therapeutics/gene-therapy)

• [Acquired Medicines Co. (2019, $9.7B) - cardiovascular](/genes/ar)
• [Acquired AveXis (2019, $8.7B) - gene therapy (Zolgensma)](/therapeutics/gene-therapy)
• [Ongoing partnerships for neuroscience programs](/genes/ar)

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease) - Early-stage AD research programs
• [Parkinson's Disease](/diseases/parkinsons-disease) - LRRK2 inhibitor programs
• [Clinical Trials in AD](/clinical-trials/alzheimers-disease) - Novartis AD trials
• [LRRK2](/genes/lrrk2) - Target of Parkinson's programs

References